혈액암을 표적으로 한 키메라항원수용체-T 세포 (CAR-T) 치료법

초록

Immunotherapy has demonstrated significant potential for the treatment of patients with hematologic malignancies and solid tumors. Among the many immunotherapy treatments, chimeric antigen receptor-T cell (CAR-T) therapy is the most promising treatment. The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. Currently, CAR-T therapy has many successful clinical results for hematologic malignancies. However, CAR-T has side effects and limits on anti-cancer effectiveness and persistence. Thus, a new CAR-T model is being developed to improve these problems. Although the new CAR-T model still needs more clinical trials, recent clinical trials have reported improvements over traditional CAR-T.

키워드